State Street’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-13,551
| Closed | -$9K | – | 3856 |
|
|
2017
Q4 | $9K | Hold |
13,551
| – | – | ﹤0.01% | 3717 |
|
|
2017
Q3 | $4K | Hold |
13,551
| – | – | ﹤0.01% | 3759 |
|
|
2017
Q2 | $6K | Hold |
13,551
| – | – | ﹤0.01% | 3690 |
|
|
2017
Q1 | $16K | Hold |
13,551
| – | – | ﹤0.01% | 3627 |
|
|
2016
Q4 | $19K | Sell |
13,551
-300
| -2% | -$522 | ﹤0.01% | 3616 |
|
|
2016
Q3 | $29K | Hold |
13,851
| – | – | ﹤0.01% | 3518 |
|
|
2016
Q2 | $21K | Hold |
13,851
| – | – | ﹤0.01% | 3657 |
|
|
2016
Q1 | $13K | Hold |
13,851
| – | – | ﹤0.01% | 3689 |
|
|
2015
Q4 | $16K | Hold |
13,851
| – | – | ﹤0.01% | 3666 |
|
|
2015
Q3 | $103K | Sell |
13,851
-8,700
| -39% | -$66.5K | ﹤0.01% | 3535 |
|
|
2015
Q2 | $161K | Sell |
22,551
-339,489
| -94% | -$2.64M | ﹤0.01% | 3506 |
|
|
2015
Q1 | $3.11M | Buy |
362,040
+2,581
| +0.7% | +$23.1K | ﹤0.01% | 2828 |
|
|
2014
Q4 | $3.59M | Sell |
359,459
-733,156
| -67% | -$6.25M | ﹤0.01% | 2746 |
|
|
2014
Q3 | $10.8M | Buy |
1,092,615
+171,487
| +19% | +$2.54M | ﹤0.01% | 2135 |
|
|
2014
Q2 | $15.9M | Sell |
921,128
-165,508
| -15% | -$2.7M | ﹤0.01% | 1962 |
|
|
2014
Q1 | $19.3M | Sell |
1,086,636
-601,248
| -36% | -$11.6M | ﹤0.01% | 1812 |
|
|
2013
Q4 | $30.9M | Buy |
1,687,884
+940,136
| +126% | +$17.8M | ﹤0.01% | 1472 |
|
|
2013
Q3 | $20M | Buy |
747,748
+464,096
| +164% | +$9.95M | ﹤0.01% | 1703 |
|
|
2013
Q2 | $5.23M | Buy |
+283,652
| New | +$5.01M | ﹤0.01% | 2438 |
|
State Street's RPRX Position: Q1 2018 in Review
State Street sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 13,551 shares — an estimated $9K sold.
State Street first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $30.9M in Q4 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- State Street reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- State Street sold 13,551 Repros Therapeutics Inc. shares in Q1 2018, an estimated $9K.
- State Street first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
- State Street's Repros Therapeutics Inc. position peaked at $30.9M in Q4 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on State Street's 13F filing for Q1 2018, filed 15 May 2018.